News Articles

Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of... NEUCHATEL, Switzerland. -Saturday 23 November 2019  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers at Nippon Medical School in Tokyo, Japan used Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® (RAM®), acoustic respiration...

Masimo Announces CE Marking of Radius Capnography™ for the Root® Patient Monitoring and Connectivity Platform ... -Friday 1 November 2019  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that Radius Capnography™, a portable real-time capnograph with wireless Bluetooth® connectivity, has received CE marking. Radius Capnography connects with the Root® Patient Monitoring and Connectivity Platform to provide seamless,...

Study Investigates the Ability of Masimo Noninvasive, Continuous Hemoglobin (SpHb®) to Provide Earlier... -Monday 23 September 2019  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that in a study published in Injury, researchers used Masimo SpHb® – noninvasive, continuous hemoglobin monitoring – to investigate possible delays in the detection of perioperative anemia assessed using invasive, intermittent...

Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, to Reduce Hyperoxia in Critically Ill... -Monday 26 August 2019  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today that in a randomized controlled study involving 150 ICU patients recently published as a letter in Intensive Care Medicine, researchers investigated whether monitoring with Masimo ORi™ (Oxygen Reserve Index) could reduce the time...

Study Demonstrates Reduction in Mortality Using Masimo Noninvasive, Continuous Hemoglobin (SpHb®) and Pleth... -Thursday 8 August 2019  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that in a study published in the Journal of Clinical Monitoring and Computing, researchers investigated the effects of implementing a hospital-wide fluid and blood administration protocol using two Masimo measurements: noninvasive,...

Masimo Announces CE Marking of Neonatal Indication for Noninvasive, Continuous Hemoglobin Monitoring... -Tuesday 6 August 2019  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the CE marking of SpHb®, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients (< 3 kg). With this clearance, the benefits of SpHb are available for patients of all ages in CE mark countries. SpHb for...

Study Investigates the Ability of Continuous Noninvasive Hemoglobin Monitoring with Masimo SpHb® to... -Monday 22 July 2019  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to detect the development of acute hemodilution after graded fluid...

New Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, As an Indicator to Avoid Hyperoxia During... -Tuesday 16 July 2019  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to serve as a noninvasive indicator of the arterial partial pressure of...

New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive... -Tuesday 21 May 2019  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians...

Masimo and Mindray Announce Expanded Partnership -Monday 13 May 2019  

Mindray to Offer Masimo SET® Pulse Oximetry in its Patient Monitoring Devices in Additional Countries Beyond the United States (BUSINESS WIRE) -- Masimo (NASDAQ: MASI) and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE: 300760) announced today that they have entered into a...

Masimo Announces First CE-marked Third-party Masimo Open Connect® Module for the... -Monday 29 April 2019  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) and Mdoloris Medical Systems announced today the CE marking of the Mdoloris Analgesia Nociception Index (ANI®) module for the Masimo Root® Patient Monitoring and Connectivity Hub, the first commercially available result of a Masimo Open...

New Study Investigates Cerebral Oxygenation Normative Values Using Masimo O3® Regional Oximetry -Wednesday 17 April 2019  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the findings of a study, recently published in Anaesthesia and Intensive Care, in which researchers at Austin Hospital in Melbourne, Australia sought to measure cerebral oxygenation in a large cohort of healthy volunteers, using Masimo...

Masimo Announces CE Marking of Pediatric Indication for Next Generation SedLine® Brain Function... -Tuesday 5 March 2019  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine® brain function monitoring for pediatric patients (1-18 years of age). With this clearance, the benefits of Next Generation SedLine are available for all patients one year old and above in CE...

New Case Series Investigates the Combined Use of Masimo SedLine® Brain Function Monitoring and... -Tuesday 26 February 2019  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a series of four clinical cases, recently published in the Canadian Journal of Anesthesiology, in which researchers at the University of Montreal found that combined use of Masimo SedLine® brain function monitoring and...

Saudi Arabia Ministry of Health and Masimo Announce Automation of National Neonatal CCHD Screening Process Using Masimo... -Monday 18 February 2019  

(BUSINESS WIRE) -- Recently at Arab Health 2019, the Saudi Arabia Ministry of Health (MOH) and Masimo (NASDAQ: MASI) jointly announced the implementation of an automation solution designed to streamline the process of critical congenital heart disease (CCHD) screening of newborns using Masimo...

International Consensus Statement on Postoperative Anemia Management Recommends Noninvasive Hemoglobin Measurement... -Wednesday 14 November 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today that a new consensus statement on postoperative anemia management was published in Anaesthesia by an international panel of clinicians specializing in patient blood management, which includes clear guidance on the use and benefits of...

New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated... -Tuesday 2 October 2018  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Angers in France investigated the ability of Masimo ORi™ (Oxygen Reserve Index)...

New Study Compares Two Methods of Guiding Goal-Directed Fluid Therapy, Noninvasive MasimoPVi® and... -Thursday 6 September 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a study recently published in BMC Anesthesiology in which researchers at University Hospital Linköping, Sweden, compared the performance of goal-directed fluid therapy (GDFT) using invasive esophageal Doppler to GDFT...

New Study Evaluates the Ability of Masimo ORi™ to Reflect Oxygenation During Moderate Hyperoxia -Tuesday 28 August 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a study recently published in Anesthesia & Analgesia in which researchers at the University of Groningen, the Netherlands, and Ghent University, Belgium, investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to...

New Study Investigates the Utility of Home Monitoring Using Masimo SET® Pulse Oximetry to Screen Children... -Tuesday 14 August 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which children with Down syndrome (DS) – who are at high risk...